ArthroCare (Austin, Texas) shares may be trading less on fundamentals and more on the firm's take-out potential, according to Canaccord Genuity (Toronto) analyst William Plovanic. The med-tech analyst penned his thoughts regarding ArthroCare as a take-out target in a 13-page report released Tuesday.

Exact Sciences (Madison, Wisconsin) said it has submitted to the FDA the final module of its PMA application for Cologuard, the company's stool DNA (sDNA) colorectal cancer screening test. The final module, which is comprised of data from the company's DeeP-C clinical trial, completes the company's PMA application for the product.